Skip to main content

Table 2 CEA, CYFRA 21-1 and NSE variation according to response to nivolumab

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

  Median (%) Range (%) p-value
CEA
No responder + 31 − 79; + 498 0.005
Responder − 9 − 92: + 88  
CYFRA21-1
No responder + 72 − 62; + 508 < 0.001
Responder − 37 − 98; + 2220  
NSE
No responder + 20 − 64; + 182 0.012
Responder − 14 − 79; + 71